title: Progesterone modulation of gonadotropin secretion by dispersed rat pituitary cells in culture. II. Intracellular metabolism and progestin receptors.
abstract: Dispersed, estradiol (E2)-treated, rat pituitary cell cultures were used to examine the intracellular processing of progesterone (P) associated with its modulation of gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone (LH) secretion. Enhancement and suppression of LH release was only observed with acute and chronic exposures to P or other naturally occurring and synthetic progestins avidly bound by pituitary progestin receptors; such responses were inhibited by cotreatment with the antiprogestin RU486 but not with the antiandrogen flutamide, illustrating the importance of the P + receptor interactions. However, cotreatment with a 100-fold molar excess of the 5 alpha-reductase inhibitor 17 beta-N,N-diethyl-carbamoyl-4-methyl-4-aza-5 alpha-androstan-3-one (4-MA) had no effect on the expression of P's modulatory actions. Additional studies using different E2 pretreatments revealed that P enhanced LH release when progestin receptor levels were elevated. Moreover, the magnitude and duration of P's influences on LH release increased in cells with higher receptor levels. However, there were several instances in which progestin receptor level and P modulation of LH release did not correlate. In several instances E2-induced progestin receptor levels stabilized at a maximal level whereas P enhancement of LH secretion continued to increase in size and duration. These findings underscore the importance of progestin receptors for P-induced modulation of LH secretion and illustrate that 5 alpha-reduction and further metabolism of P is not obligatory for the expression of these responses. In addition, our data demonstrate that the important cellular mechanisms underlying E2 priming of gonadotroph responsiveness to P entail the induction of progestin receptor levels and other as yet unidentified cellular processes.
authors.affiliation: Laboratory of Neuroendocrinology, Rockefeller University, New York, NY 10021.
authors.forename: L C
authors.initials: LC
authors.lastname: Krey
authors.forename: F
authors.initials: F
authors.lastname: Kamel
authors.forename: N J
authors.initials: NJ
authors.lastname: MacLusky
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology; D000818:Animals; D001378:Azasteroids / Q000494:pharmacology; D002478:Cells, Cultured; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000378:metabolism; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism*; D011374:Progesterone / Q000494:pharmacology*; D011372:Progestins / Q000494:pharmacology; D051381:Rats; D011980:Receptors, Progesterone / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000726:Androgen Antagonists; D001378:Azasteroids; D011372:Progestins; D011980:Receptors, Progesterone; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; C031563:17-N,N-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one; D007986:Luteinizing Hormone